<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04616053</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A02905-34</org_study_id>
    <nct_id>NCT04616053</nct_id>
  </id_info>
  <brief_title>IMPACT Intervention</brief_title>
  <official_title>A Randomised Controlled Trial to Evaluate the Effectiveness of a Multidisciplinary Team Intervention on Glycaemic Control for Disadvantaged Type 2 Diabetes Patients in France.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pole de Sante Chambery Nord</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pole de Sante Chambery Nord</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction :&#xD;
&#xD;
      The prevalence of type 2 diabetes is increasing in France, especially in deprived districts.&#xD;
&#xD;
      The Itineraires Medico-sociaux Programme d'Accompagnement sur un Territoire (IMPACT)&#xD;
      intervention is intended for disadvantaged patients with a chronic disease (not only type 2&#xD;
      diabetes).&#xD;
&#xD;
      The IMPACT intervention offers coordinated and patient-centered care by a multidisciplinary&#xD;
      team with an empowerment approach. This personalised intervention lasts 6 months.&#xD;
&#xD;
      This study aims to evaluate the effect of 6 months IMPACT intervention on glycaemic control&#xD;
      (glycated haemoglobin - HbA1c) of patients with type 2 diabetes in deprived districts.&#xD;
&#xD;
      Method :&#xD;
&#xD;
      This will be a randomised, controlled, parallel group, multicenter, open-label trial. 140&#xD;
      adults with type 2 diabetes will be randomised in two arms : IMPACT intervention group (n :&#xD;
      70) and usual care group (n : 70). The primary outcome is change in glycated haemoglobin&#xD;
      (HbA1c) from baseline to 6 months. The primary outcome will be analysed using a linear mixed&#xD;
      effects model.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomised, controlled, parallel group, multicenter, open-label trial.&#xD;
      Patients will be recruited among patients with type 2 diabetes referred to the IMPACT&#xD;
      intervention.&#xD;
&#xD;
      144 patients will be randomised in two arms : IMPACT intervention group (n : 72) and usual&#xD;
      care group (n : 72).&#xD;
&#xD;
      IMPACT intervention : a referent is assigned to the patient. A referent is a health worker&#xD;
      (nurse, nutritionist, psychologist …). Patient builds with his referent a free care program.&#xD;
      The patient can choose individual consultation (for example : nutrition, tabacology,&#xD;
      psychology …) and/or collective care (for example : patient education, physical activity,&#xD;
      relaxation …). A community health worker can help patients with his health administrative&#xD;
      procedures.&#xD;
&#xD;
      Patients will have 3 visits. First visit (inclusion visit) : investigator collects baseline&#xD;
      characteristics (sociodemographic data, comorbidity, treatment, diabetes complications,&#xD;
      weight, height, body mass index, impedancemetry, HbA1c, lipids, creatinine,&#xD;
      albuminuria/creatinuria ratio). Then the patient will be randomised.&#xD;
&#xD;
      Second visit (midpoint visit) : investigator collects weight, BMI, impedancemetry, HbA1c and&#xD;
      adverse events Third visit (end point visit) : investigator collects weight, BMI,&#xD;
      impedancemetry, HbA1c, lipids and adverse events.&#xD;
&#xD;
      Analysis : The primary outcome is change in glycated haemoglobin (HbA1c) from baseline to 6&#xD;
      months. The primary outcome will be analysed using a linear mixed effects model. Study&#xD;
      groups, districts, time, group-time interaction and district-group interaction will be&#xD;
      included as fixed effects. The model will include patients as a random effect. Sub-group&#xD;
      analysis will be made with baseline HbA1c, sex, age, Epices score (French precarity score)&#xD;
      and diabetes duration. The robustness of the model will be tested by replacing missing data&#xD;
      with multiple imputation methods. The same statistical modelling approach will be used for&#xD;
      the secondary outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>From baseline to 6 months</time_frame>
    <description>Change in glycated haemoglobin (HbA1c)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>From baseline to 3 months</time_frame>
    <description>Change in glycated haemoglobin (HbA1c)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>At Months 3 and 6 from baseline</time_frame>
    <description>Change in weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index</measure>
    <time_frame>At Months 3 and 6 from baseline</time_frame>
    <description>Change in body mass index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body fat mass (Bioelectrical impedance analysis)</measure>
    <time_frame>At Months 3 and 6 from baseline</time_frame>
    <description>Change in body fat mass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body fat percentage (Bioelectrical impedance analysis)</measure>
    <time_frame>At Months 3 and 6 from baseline</time_frame>
    <description>Change in body fat percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle mass (Bioelectrical impedance analysis)</measure>
    <time_frame>At Months 3 and 6 from baseline</time_frame>
    <description>Change in muscle mass.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids - HDL cholesterol</measure>
    <time_frame>From baseline to 6 months</time_frame>
    <description>Change in HDL cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids - LDL cholesterol</measure>
    <time_frame>From baseline to 6 months</time_frame>
    <description>Change in LDL cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids - triglycerides</measure>
    <time_frame>From baseline to 6 months</time_frame>
    <description>Change in triglycerides</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMPACT intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual care</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>IMPACT intervention</intervention_name>
    <description>A referent is assigned to the patient. A referent is a health worker (nurse, nutritionist, psychologist …). Patient builds with his referent a free care program (without condition or limit). The patient can choose individual consultation (for example : nutrition, tabacology, psychology …) and/or collective care (for example : patient education, physical activity, relaxation …). A community health worker can help patient with his health administrative procedures. This intervention lasts 6 months.</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with type 2 diabetes&#xD;
&#xD;
          -  Inclusion HbA1c &gt; 7.5%&#xD;
&#xD;
          -  Live in Hauts de Chambéry, Biollay or Renaudie district&#xD;
&#xD;
          -  Be able to give written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe cognitive or psychological disorder that may affect study understanding&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Had IMPACT intervention in the previous 24 months&#xD;
&#xD;
          -  Concurrent participation in another study&#xD;
&#xD;
          -  Concurrent participation in another diabetes educational care program&#xD;
&#xD;
          -  Life expectancy less than 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Donatien Talon, Resident</last_name>
    <phone>+33679230064</phone>
    <email>donatien.talon@gmail.com</email>
  </overall_contact>
  <reference>
    <citation>Tricco AC, Ivers NM, Grimshaw JM, Moher D, Turner L, Galipeau J, Halperin I, Vachon B, Ramsay T, Manns B, Tonelli M, Shojania K. Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis. Lancet. 2012 Jun 16;379(9833):2252-61. doi: 10.1016/S0140-6736(12)60480-2. Epub 2012 Jun 9. Review.</citation>
    <PMID>22683130</PMID>
  </reference>
  <reference>
    <citation>Attridge M, Creamer J, Ramsden M, Cannings-John R, Hawthorne K. Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2014 Sep 4;(9):CD006424. doi: 10.1002/14651858.CD006424.pub3. Review.</citation>
    <PMID>25188210</PMID>
  </reference>
  <reference>
    <citation>Captieux M, Pearce G, Parke HL, Epiphaniou E, Wild S, Taylor SJC, Pinnock H. Supported self-management for people with type 2 diabetes: a meta-review of quantitative systematic reviews. BMJ Open. 2018 Dec 14;8(12):e024262. doi: 10.1136/bmjopen-2018-024262.</citation>
    <PMID>30552277</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 27, 2020</study_first_submitted>
  <study_first_submitted_qc>November 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>November 1, 2020</last_update_submitted>
  <last_update_submitted_qc>November 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>primary health care</keyword>
  <keyword>patient-centered care</keyword>
  <keyword>poverty areas</keyword>
  <keyword>vulnerable populations</keyword>
  <keyword>Glycated Hemoglobin A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

